Autolus Therapeutics plc - ADR
NASDAQ:AUTL
| Market Cap (Intraday) | 1.08B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $3.79 |
| 50-Day MA | $3.95 |
| 200-Day MA | $4.86 |
Autolus Therapeutics plc - ADR Stock, NASDAQ:AUTL
The Mediaworks, 191 Wood Lane, London, Greater London W12 7FP
United Kingdom
Phone: +44.20.3829.6230
Number of Employees: 463
Description
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.